



MANAGEMENT OF BRCA POSITIVE OVARIAN AND BREAST CANCER

Grand Hotel Union Ljubljana, Slovenia
- Thursday, 7th of April 2016 -

PROGRAM

15.30 - 16.00	<i>Participants gathering Silver room</i>
16.00 - 16.05	Opening and welcome speech, <i>M. Krajc</i>
16.05 - 16.55	PARP inhibitors in ovarian cancer – a look back and a look forward, <i>S. Kaye</i>
16.55 - 17.45	BRCA1/2 associated breast cancer, <i>G. Evans</i>
17.45 - 18.00	<i>Coffee Break</i>
18.00 - 19.30	Moderated discussion and case presentations: <ul style="list-style-type: none">• BRCA genes and genes beyond BRCA – genetic testing from germline to somatic mutations - laboratory experiences, <i>S. Novaković</i>• Cancer genetic counselling and testing - from preventive medicine to treatment, <i>M. Krajc</i>• First Slovenian experiences with olaparib in treatment of ovarian cancer, <i>E. Škof</i>• Surgical treatment of BRCA positive breast cancer patients - 15 years of Slovenian experiences, <i>J. Žgajnar</i>
19.30	<i>Dinner Blue room</i>

Prof. Gareth EVANS, MD, PhD;

Professor of Medical Genetics and Cancer Epidemiology, Genomic Medicine; Manchester Academic Health Science Centre, The University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Saint Mary's Hospital, UK

Professor Evans has established a national and international reputation in clinical and research aspects of cancer genetics, particularly in neuro-fibromatosis and breast cancer. He has developed a clinical service for cancer genetics in the North West Region of England. He is an important opinion leader nationally through membership of committees and was chairman of the NICE Familial Breast Cancer Guideline Development Group (2002-2010) and is now clinical lead (2011-). He lectures throughout the UK and internationally on hereditary breast cancer and cancer syndromes. He has developed a national training program for clinicians, nurses and genetic counsellors in breast cancer genetics and established

a system for risk assessment and counselling for breast cancer in Calman breast units implemented through a training course (1998-2011). He has published 603 peer reviewed research publications; 225 as first or senior author. He has published over 90 reviews and chapters and has had a book published by Oxford University Press on familial cancer.

Prof. Stan KAYE, MD, PhD;

Professor of Medical Oncology, Royal Marsden NHS Foundation Trust; UK
Professor Stan Kaye is a consultant (and former Head) in the Drug Development Unit (DDU) at the ICR and The Royal Marsden NHS Foundation Trust. The DDU is one of the world's largest Phase I Units, taking part in approximately 30 current new drug trials. These include the first studies conducted with the PARP inhibitor, olaparib.

Professor Kaye joined the ICR in September 2000 after 20 years in Glasgow, 15 of which were spent as Head of Medical Oncology at Glasgow University.

He qualified in medicine in 1972 in London and completed training in medicine and oncology in London and Australia. His major specialties include drug development, drug resistance and ovarian cancer.

Prof. Kaye is the author of more than 350 peer reviewed papers; he sits on the Editorial Board of 12 cancer journals and on the Advisory Boards of 5 cancer institutes. Until recently, he had a busy clinical practice at The Royal Marsden, with responsibility for the care of patients with gynaecological cancers as well as those in the Drug Development Unit. He says his field of cancer research is "rewarding and exciting", but is hoping he will now have more time to see the world.

Organisers: Slovenian Senologic Society and Institute of Oncology Ljubljana; **Scientific and Organizing Committee:** Ana Blatnik, Simona Borštnar, Mateja Krajc, Srdjan Novaković, Erik Škof, Janez Žgajnar; **Invited International Speakers:** Gareth Evans, Stan Kaye; **Sponsored by:** AstraZeneca UK Limited, Branch Office in Slovenia; Roche d.o.o.